SCHEMBL2660048

SCHEMBL2660048

CN1C(=O)C2CNCC2C1=O

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.33
HTR2A P28223 7/20 0.32
HTR2C P28335 7/20 0.32
HTR2B P41595 7/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2970076 0.97 HTR2A (0.33) ACHEHTR2AHTR2CHTR2B
SCHEMBL5230146 0.84 PLG (0.33)
SCHEMBL23379624 0.75 ACHE (0.36) ACHE
SCHEMBL22016051 0.75 ACHE (0.36) ACHE
SCHEMBL19711768 0.70 KMT2A (0.36) ACHE
SCHEMBL15856680 0.70 ACHE (0.38) ACHE
SCHEMBL12552817 0.70 MAPK1 (0.41) ACHE
SCHEMBL13206576 0.70 ALDH1A1 (0.41) ACHE
SCHEMBL23422468 0.70 MAPK1 (0.41) ACHE
SCHEMBL761658 0.70 ALDH1A1 (0.41) ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10246470-B2 Heterocyclic compounds CADILA HEALTHCARE LIMITED (IN) 2019-04-02 US disclosed
US-10011609-B2 Heterocyclic compounds CADILA HEALTHCARE LIMITED (IN) 2018-07-03 US disclosed
US-10011609-B2 Heterocyclic compounds CADILA HEALTHCARE LIMITED (IN) 2018-07-03 US disclosed
US-20160257701-A1 NOVEL HETEROCYCLIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2016-09-08 US disclosed
US-20160257701-A1 NOVEL HETEROCYCLIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2016-09-08 US disclosed
WO-2015097713-A1 NOVEL HETEROCYCLIC COMPOUNDS CADILA HEALTHCARE LIMITED (IN) 2015-07-02 WO disclosed
EP-2074119-A1 INDOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-07-01 EP disclosed
WO-2008050821-A1 INDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011609-B2 Heterocyclic compounds GPR55, GPR68, GPR65 ACHE 4077/4885HTR2A 211/4885HTR2C 233/4885
US-10246470-B2 Heterocyclic compounds HAAO, HK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ACHE 1801/4885HTR2A 327/4885HTR2C 84/4885
US-20160257701-A1 NOVEL HETEROCYCLIC COMPOUNDS GPR55, GPR68, GPR65 ACHE 4082/4885HTR2A 195/4885HTR2C 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.